Insider Transactions in Q4 2022 at Karuna Therapeutics, Inc. (KRTX)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 21
2022
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
7,100
+27.9%
|
$14,200
$2.92 P/Share
|
|
Dec 16
2022
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,867
+12.93%
|
$106,803
$9.2 P/Share
|
|
Dec 09
2022
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-13.92%
|
$1,000,000
$200.76 P/Share
|
|
Dec 09
2022
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.01%
|
$40,000
$8.24 P/Share
|
|
Dec 02
2022
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
750
+1.42%
|
$3,750
$5.1 P/Share
|
|
Dec 01
2022
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
15,000
-57.14%
|
$3,420,000
$228.3 P/Share
|
|
Nov 15
2022
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
16,500
-62.33%
|
$3,712,500
$225.85 P/Share
|
|
Nov 15
2022
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,500
+38.4%
|
$148,500
$9.2 P/Share
|
|
Nov 11
2022
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+2.44%
|
$10,000
$5.1 P/Share
|
|
Nov 10
2022
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
15,000
-37.04%
|
$3,375,000
$225.98 P/Share
|
|
Nov 09
2022
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-25.0%
|
$1,080,000
$216.0 P/Share
|
|
Nov 09
2022
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+20.0%
|
$45,000
$9.2 P/Share
|
|
Nov 03
2022
|
Andrew Craig Miller President of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+3.6%
|
$4,000
$2.92 P/Share
|
|
Nov 01
2022
|
Andrew Craig Miller President of R&D |
SELL
Open market or private sale
|
Direct |
15,000
-28.04%
|
$3,375,000
$225.08 P/Share
|
|
Oct 11
2022
|
Laurie J Olson |
SELL
Open market or private sale
|
Direct |
1,000
-100.0%
|
$205,000
$205.63 P/Share
|
|
Oct 11
2022
|
Laurie J Olson |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+50.0%
|
$84,000
$84.86 P/Share
|
|
Oct 10
2022
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-25.0%
|
$1,035,000
$207.51 P/Share
|
|
Oct 10
2022
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+20.0%
|
$45,000
$9.2 P/Share
|
|
Oct 04
2022
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
400
-3.86%
|
$93,200
$233.2 P/Share
|
|
Oct 03
2022
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,100
-10.45%
|
$947,100
$231.11 P/Share
|